Efficacy of Yangyin Yiqi Huoxue Granule (养阴益气活血颗粒) in Treatment of Ischemic Stroke Patients with Qi-Yin Deficiency and Blood Stasis Syndrome: A Randomized, Double-Blind, Multicenter, Phase-2 Clinical Trial
Back to article page
|Updated:2021-09-24
|
Efficacy of Yangyin Yiqi Huoxue Granule (养阴益气活血颗粒) in Treatment of Ischemic Stroke Patients with Qi-Yin Deficiency and Blood Stasis Syndrome: A Randomized, Double-Blind, Multicenter, Phase-2 Clinical Trial
Chinese Journal of Integrative MedicinePages: 1-8
Affiliations:
Author bio:
Funds:
Supported by the National Natural Science Foundation of China (No. 81630105, No. 81374053, No. 81173647), Zhejiang Provincial Natural Science Foundation of China (No. LZ17H270001) and Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents (No. 2018R1002),Conflict of Interest,The authors declare that they have no competing interests.,Authors’ Contributions,Wan HT, Yang JH, and He Y contributed to the conception and design of the study. Xu B and Ai CS were the principal investigator who conducted the pilot study. Wan HF and Bie XD collected data, Zhou HF and Yu L performed data analysis, Wang Y drafted the manuscript. All authors contributed to further writing of the manuscript, and read and approved the final version.
DOI:
CLC:
Scan for full text
Yu Wang, Jie-hong Yang, Hai-tong Wan, et al. Efficacy of Yangyin Yiqi Huoxue Granule (养阴益气活血颗粒) in Treatment of Ischemic Stroke Patients with Qi-Yin Deficiency and Blood Stasis Syndrome: A Randomized, Double-Blind, Multicenter, Phase-2 Clinical Trial. [J/OL]. 1-8(0)
DOI:
Yu Wang, Jie-hong Yang, Hai-tong Wan, et al. Efficacy of Yangyin Yiqi Huoxue Granule (养阴益气活血颗粒) in Treatment of Ischemic Stroke Patients with Qi-Yin Deficiency and Blood Stasis Syndrome: A Randomized, Double-Blind, Multicenter, Phase-2 Clinical Trial. [J/OL]. 1-8(0)DOI:
Efficacy of Yangyin Yiqi Huoxue Granule (养阴益气活血颗粒) in Treatment of Ischemic Stroke Patients with Qi-Yin Deficiency and Blood Stasis Syndrome: A Randomized, Double-Blind, Multicenter, Phase-2 Clinical Trial
Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial
Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents: A Randomized Controlled Trial
Related Author
No data
Related Institution
Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China;Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China;National Center for Infectious Diseases, Beijing, China;Peking University Ditan Teaching Hospital, Beijing, China;Central of Integrated Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China;China Traditional Chinese Medicine Holdings Co. Limited, Guangzhou, China
Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China;Acupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai, China;Department of Health Management, The First Affiliated Hospital of Nanchang University, Nanchang, China;Jiangxi Provincial Traditional Chinese Medicine Nephropathy Clinical Research Center, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi Province, China;Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China;Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai, China